# Bio-Rad Laboratories

US life-science products company (NYSE: BIO, est. 1952) — Nuvia mixed-mode and ion-exchange chromatography resins, NGC FPLC systems, CHT Ceramic Hydroxyapatite for mAb polishing; broad diagnostics and life-science research portfolio alongside biopharma purification business.

Source: https://en.bioecon.ru/companies/bio-rad/
Updated: 2026-06-19

- Country: United States
- Revenue: $2.8B
- Employees: ~7,800 emp

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Revenue | $2.58 billion in 2025 | https://www.sec.gov/Archives/edgar/data/12208/000001220826000021/bio-radannualreport2025.pdf |
| Headcount | approximately 7,450 employees as of December 31, 2025 | https://www.sec.gov/Archives/edgar/data/12208/000001220826000021/bio-radannualreport2025.pdf |
| Production site | Global manufacturing network including facilities in Hercules and Irvine (California), Seattle/Woodinville (Washington), Singapore, France, Germany, Switzerland, Belgium, and China | https://www.bio-rad.com/en-us/feature/quality-management-systems-certificates.html, https://www.sec.gov/Archives/edgar/data/12208/000001220826000021/bio-radannualreport2025.pdf |
| Certification | ISO 9001, ISO 13485:2016, and Medical Device Single Audit Program (MDSAP) compliance | https://www.bio-rad.com/en-us/feature/quality-management-systems-certificates.html, https://www.bio-rad.com/sites/default/files/2025-06/QS6_118577_0016.pdf, https://www.sec.gov/Archives/edgar/data/12208/000001220826000021/bio-radannualreport2025.pdf |
| Regulatory approval | Products subject to FDA (CDRH/CBER) regulation; diagnostic products meet EU IVDR requirements | https://www.sec.gov/Archives/edgar/data/12208/000001220825000019/bio-rad2024annualreport10xk.pdf, https://www.sec.gov/Archives/edgar/data/12208/000001220826000021/bio-radannualreport2025.pdf |
| Funding | Invested in Geneoscopy and Oncocyte; announced intent to acquire Stilla Technologies (as of February 2025) [medium confidence] | https://investors.bio-rad.com/press-releases/news-details/2025/Bio-Rad-Reports-Fourth-Quarter-and-Full-Year-2024-Financial-Results/default.aspx, https://investors.bio-rad.com/press-releases/news-details/2026/Bio-Rad-Reports-Second-Quarter-2026-Financial-Results/, https://www.sec.gov/Archives/edgar/data/12208/000001220826000021/bio-radannualreport2025.pdf |
| Capacity | Production capacity is managed based on normal facility capacity; impacted by consolidations of manufacturing sites (e.g., European sites into Singapore hub) [medium confidence] | https://www.bio-rad.com/webroot/web/pdf/corporate/literature/2004_annual.pdf |

Independent sources: sec.gov

## Technologies

- [Downstream Purification & Bioseparation](https://en.bioecon.ru/technology/downstream-purification-bioseparation/)
- [Home DNA extraction kits](https://en.bioecon.ru/technology/home-dna-extraction-kits/)
- [Invasive-species biomonitoring via eDNA](https://en.bioecon.ru/technology/edna-invasive-species-biomonitoring/)
- [Wastewater-based epidemiology](https://en.bioecon.ru/technology/wastewater-based-epidemiology/)